专题：Hepatocellular Carcinoma Treatment and Prognosis

This cluster of papers focuses on the management, diagnosis, and treatment of hepatocellular carcinoma (HCC), also known as liver cancer. It covers various aspects including clinical practice guidelines, radiofrequency ablation, use of sorafenib, liver resection, and survival rates.
最新文献
Left Lung Ultracentral, Radioresistant Metastasis: A Double Dilemma

article Full Text OpenAlex

Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma

article Full Text OpenAlex

Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma

article Full Text OpenAlex

Enhancing Capsule on Dynamic Liver CT: Association With Hepatocellular Carcinoma Diagnosis Using LI-RADS Version 2018

article Full Text OpenAlex

Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study.

article Full Text OpenAlex

Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis

article Full Text OpenAlex

Artificial intelligence-based personalized treatment strategies for unresectable hepatocellular carcinoma: integrating HSP90α for prognosis and survival prediction

article Full Text OpenAlex

Cancer Vaccines: Molecular Mechanisms, Clinical Progress, and Combination Immunotherapies with a Focus on Hepatocellular Carcinoma

article Full Text OpenAlex

Hepatocellular carcinoma with macrovascular invasion: Review and survival meta-analysis of initial local therapy using minimal prognostic criteria

article Full Text OpenAlex

MRI ‐Based Score to Predict Retreatment Response for Viable Hepatocellular Carcinomas After Transarterial Chemoembolization

article Full Text OpenAlex

近5年高被引文献
Hepatocellular carcinoma

review Full Text OpenAlex 2095 FWCI278.9293

Global burden of primary liver cancer in 2020 and predictions to 2040

article Full Text OpenAlex 1858 FWCI267.9297

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

article Full Text OpenAlex 1450 FWCI299.7986

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

article Full Text OpenAlex 1318 FWCI171.3185

Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy

review Full Text OpenAlex 703 FWCI153.1228

Management of Hepatocellular Carcinoma

review Full Text OpenAlex 678 FWCI142.2902

Evolving therapeutic landscape of advanced hepatocellular carcinoma

review Full Text OpenAlex 663 FWCI54.8222

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

article Full Text OpenAlex 600 FWCI124.6599

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

article Full Text OpenAlex 587 FWCI58.4039

Current status and future trends of the global burden of MASLD

review Full Text OpenAlex 560 FWCI222.6945